BMY
Income statement / Annual
Last year (2023), Bristol-Myers Squibb Company's total revenue was $45.01 B,
a decrease of 2.50% from the previous year.
In 2023, Bristol-Myers Squibb Company's net income was $8.03 B.
See Bristol-Myers Squibb Company,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$45.01 B
|
$46.16 B
|
$46.39 B
|
$42.52 B
|
$26.15 B
|
$22.56 B
|
$20.78 B
|
$19.43 B
|
$16.56 B
|
$15.88 B
|
| Cost of Revenue |
$10.69 B |
$10.14 B |
$9.94 B |
$11.77 B |
$8.08 B |
$6.55 B |
$6.07 B |
$4.95 B |
$3.91 B |
$3.93 B |
| Gross Profit |
$34.31 B |
$36.02 B |
$36.45 B |
$30.75 B |
$18.07 B |
$16.01 B |
$14.71 B |
$14.48 B |
$12.65 B |
$11.95 B |
| Gross Profit Ratio |
0.76 |
0.78 |
0.79 |
0.72 |
0.69 |
0.71 |
0.71 |
0.75 |
0.76 |
0.75 |
| Research and Development
Expenses |
$9.30 B
|
$9.51 B
|
$10.20 B
|
$11.14 B
|
$6.15 B
|
$6.35 B
|
$6.41 B
|
$4.94 B
|
$5.92 B
|
$4.53 B
|
| General & Administrative
Expenses |
$6.28 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$162.00 M
|
$91.00 M
|
$160.00 M
|
$877.00 M
|
| Selling & Marketing
Expenses |
$1.40 B
|
$7.81 B
|
$7.69 B
|
$7.66 B
|
$4.87 B
|
$4.55 B
|
$4.69 B
|
$4.91 B
|
$4.84 B
|
$4.82 B
|
| Selling, General &
Administrative Expenses |
$7.77 B
|
$7.81 B
|
$7.69 B
|
$7.66 B
|
$4.87 B
|
$4.55 B
|
$4.85 B
|
$5.00 B
|
$5.00 B
|
$5.70 B
|
| Other Expenses |
$0.00 |
$9.60 B |
$10.02 B |
$9.76 B |
$1.14 B |
$1.37 B |
$1.40 B |
$1.00 B |
$621.00 M |
$313.00 M |
| Operating Expenses |
$17.89 B |
$26.92 B |
$27.91 B |
$28.57 B |
$12.15 B |
$10.90 B |
$11.26 B |
$9.94 B |
$10.92 B |
$10.23 B |
| Cost And Expenses |
$28.41 B |
$37.06 B |
$37.85 B |
$40.34 B |
$20.23 B |
$17.44 B |
$17.33 B |
$14.89 B |
$14.83 B |
$14.17 B |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.17 B |
$1.23 B |
$1.33 B |
$1.42 B |
$656.00 M |
$183.00 M |
$196.00 M |
$167.00 M |
$184.00 M |
$203.00 M |
| Depreciation &
Amortization |
$9.81 B
|
$10.29 B
|
$10.76 B
|
$10.49 B
|
$1.81 B
|
$703.00 M
|
$872.00 M
|
$626.00 M
|
$376.00 M
|
$467.00 M
|
| EBITDA |
$19.42 B
|
$19.23 B
|
$20.19 B
|
$5.04 B
|
$7.44 B
|
$6.85 B
|
$6.20 B
|
$4.63 B
|
$2.94 B
|
$3.41 B
|
| EBITDA Ratio |
0.43 |
0.43 |
0.44 |
0.35 |
0.25 |
0.27 |
0.28 |
0.29 |
0.15 |
0.13 |
| Operating Income Ratio
|
0.38
|
0.22
|
0.22
|
0.12
|
0.21
|
0.23
|
0.17
|
0.23
|
0.1
|
0.11
|
| Total Other
Income/Expenses Net |
-$8.80 B
|
-$10.64 B
|
-$9.30 B
|
-$7.42 B
|
-$938.00 M
|
-$426.00 M
|
-$108.00 M
|
$1.45 B
|
$347.00 M
|
$667.00 M
|
| Income Before Tax |
$8.44 B |
$7.71 B |
$8.10 B |
-$6.87 B |
$4.98 B |
$6.01 B |
$5.13 B |
$5.92 B |
$2.17 B |
$2.38 B |
| Income Before Tax Ratio
|
0.19
|
0.17
|
0.17
|
-0.16
|
0.19
|
0.27
|
0.25
|
0.3
|
0.13
|
0.15
|
| Income Tax Expense |
$400.00 M |
$1.37 B |
$1.08 B |
$2.12 B |
$1.52 B |
$1.03 B |
$4.16 B |
$1.41 B |
$477.00 M |
$352.00 M |
| Net Income |
$8.03 B |
$6.33 B |
$6.99 B |
-$9.00 B |
$3.44 B |
$4.95 B |
$1.01 B |
$4.46 B |
$1.62 B |
$2.00 B |
| Net Income Ratio |
0.18 |
0.14 |
0.15 |
-0.21 |
0.13 |
0.22 |
0.05 |
0.23 |
0.1 |
0.13 |
| EPS |
3.88 |
2.97 |
3.15 |
-3.98 |
2.02 |
3.03 |
0.61 |
2.67 |
0.97 |
1.21 |
| EPS Diluted |
3.86 |
2.95 |
3.12 |
-3.98 |
2.01 |
3.03 |
0.61 |
2.65 |
0.97 |
1.2 |
| Weighted Average Shares
Out |
$2.07 B
|
$2.13 B
|
$2.22 B
|
$2.26 B
|
$1.71 B
|
$1.63 B
|
$1.65 B
|
$1.67 B
|
$1.67 B
|
$1.66 B
|
| Weighted Average Shares
Out Diluted |
$2.08 B
|
$2.15 B
|
$2.25 B
|
$2.26 B
|
$1.71 B
|
$1.64 B
|
$1.65 B
|
$1.68 B
|
$1.68 B
|
$1.67 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
